- IBDEI1C4 ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,21574,1,3,0)
- ;;=3^Sicca Syndrome w/ Myopathy
- ;;^UTILITY(U,$J,358.3,21574,1,4,0)
- ;;=4^M35.03
- ;;^UTILITY(U,$J,358.3,21574,2)
- ;;=^5011789
- ;;^UTILITY(U,$J,358.3,21575,0)
- ;;=M35.09^^70^921^57
- ;;^UTILITY(U,$J,358.3,21575,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21575,1,3,0)
- ;;=3^Sicca Syndrome w/ Oth Organ Involvement
- ;;^UTILITY(U,$J,358.3,21575,1,4,0)
- ;;=4^M35.09
- ;;^UTILITY(U,$J,358.3,21575,2)
- ;;=^5011791
- ;;^UTILITY(U,$J,358.3,21576,0)
- ;;=M35.04^^70^921^58
- ;;^UTILITY(U,$J,358.3,21576,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21576,1,3,0)
- ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
- ;;^UTILITY(U,$J,358.3,21576,1,4,0)
- ;;=4^M35.04
- ;;^UTILITY(U,$J,358.3,21576,2)
- ;;=^5011790
- ;;^UTILITY(U,$J,358.3,21577,0)
- ;;=M35.00^^70^921^59
- ;;^UTILITY(U,$J,358.3,21577,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21577,1,3,0)
- ;;=3^Sicca Syndrome,Unspec
- ;;^UTILITY(U,$J,358.3,21577,1,4,0)
- ;;=4^M35.00
- ;;^UTILITY(U,$J,358.3,21577,2)
- ;;=^5011786
- ;;^UTILITY(U,$J,358.3,21578,0)
- ;;=M32.10^^70^921^62
- ;;^UTILITY(U,$J,358.3,21578,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21578,1,3,0)
- ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
- ;;^UTILITY(U,$J,358.3,21578,1,4,0)
- ;;=4^M32.10
- ;;^UTILITY(U,$J,358.3,21578,2)
- ;;=^5011753
- ;;^UTILITY(U,$J,358.3,21579,0)
- ;;=M32.9^^70^921^61
- ;;^UTILITY(U,$J,358.3,21579,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21579,1,3,0)
- ;;=3^Systemic Lupus Erythematosus,Unspec
- ;;^UTILITY(U,$J,358.3,21579,1,4,0)
- ;;=4^M32.9
- ;;^UTILITY(U,$J,358.3,21579,2)
- ;;=^5011761
- ;;^UTILITY(U,$J,358.3,21580,0)
- ;;=M34.2^^70^921^63
- ;;^UTILITY(U,$J,358.3,21580,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21580,1,3,0)
- ;;=3^Systemic Sclerosis Induced by Drug/Chemical
- ;;^UTILITY(U,$J,358.3,21580,1,4,0)
- ;;=4^M34.2
- ;;^UTILITY(U,$J,358.3,21580,2)
- ;;=^5011780
- ;;^UTILITY(U,$J,358.3,21581,0)
- ;;=M34.81^^70^921^64
- ;;^UTILITY(U,$J,358.3,21581,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21581,1,3,0)
- ;;=3^Systemic Sclerosis w/ Lung Involvement
- ;;^UTILITY(U,$J,358.3,21581,1,4,0)
- ;;=4^M34.81
- ;;^UTILITY(U,$J,358.3,21581,2)
- ;;=^5011781
- ;;^UTILITY(U,$J,358.3,21582,0)
- ;;=M34.82^^70^921^65
- ;;^UTILITY(U,$J,358.3,21582,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21582,1,3,0)
- ;;=3^Systemic Sclerosis w/ Myopathy
- ;;^UTILITY(U,$J,358.3,21582,1,4,0)
- ;;=4^M34.82
- ;;^UTILITY(U,$J,358.3,21582,2)
- ;;=^5011782
- ;;^UTILITY(U,$J,358.3,21583,0)
- ;;=M34.83^^70^921^66
- ;;^UTILITY(U,$J,358.3,21583,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21583,1,3,0)
- ;;=3^Systemic Sclerosis w/ Polyneuropathy
- ;;^UTILITY(U,$J,358.3,21583,1,4,0)
- ;;=4^M34.83
- ;;^UTILITY(U,$J,358.3,21583,2)
- ;;=^5011783
- ;;^UTILITY(U,$J,358.3,21584,0)
- ;;=M34.9^^70^921^67
- ;;^UTILITY(U,$J,358.3,21584,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21584,1,3,0)
- ;;=3^Systemic Sclerosis,Unspec
- ;;^UTILITY(U,$J,358.3,21584,1,4,0)
- ;;=4^M34.9
- ;;^UTILITY(U,$J,358.3,21584,2)
- ;;=^5011785
- ;;^UTILITY(U,$J,358.3,21585,0)
- ;;=J84.170^^70^921^16
- ;;^UTILITY(U,$J,358.3,21585,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,21585,1,3,0)
- ;;=3^Interstitial Lung Dis w/ Progressive Fibrotic Phenotype in Dis Classd Elsewhere
- ;;^UTILITY(U,$J,358.3,21585,1,4,0)
- ;;=4^J84.170
- ;;^UTILITY(U,$J,358.3,21585,2)
- ;;=^5159208
- ;;^UTILITY(U,$J,358.3,21586,0)
- ;;=J84.178^^70^921^17
- ;;^UTILITY(U,$J,358.3,21586,1,0)
- ;;=^358.31IA^4^2
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1C4 3770 printed Feb 18, 2025@23:32:11 Page 2
- IBDEI1C4 ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,21574,1,3,0)
- +2 ;;=3^Sicca Syndrome w/ Myopathy
- +3 ;;^UTILITY(U,$J,358.3,21574,1,4,0)
- +4 ;;=4^M35.03
- +5 ;;^UTILITY(U,$J,358.3,21574,2)
- +6 ;;=^5011789
- +7 ;;^UTILITY(U,$J,358.3,21575,0)
- +8 ;;=M35.09^^70^921^57
- +9 ;;^UTILITY(U,$J,358.3,21575,1,0)
- +10 ;;=^358.31IA^4^2
- +11 ;;^UTILITY(U,$J,358.3,21575,1,3,0)
- +12 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
- +13 ;;^UTILITY(U,$J,358.3,21575,1,4,0)
- +14 ;;=4^M35.09
- +15 ;;^UTILITY(U,$J,358.3,21575,2)
- +16 ;;=^5011791
- +17 ;;^UTILITY(U,$J,358.3,21576,0)
- +18 ;;=M35.04^^70^921^58
- +19 ;;^UTILITY(U,$J,358.3,21576,1,0)
- +20 ;;=^358.31IA^4^2
- +21 ;;^UTILITY(U,$J,358.3,21576,1,3,0)
- +22 ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
- +23 ;;^UTILITY(U,$J,358.3,21576,1,4,0)
- +24 ;;=4^M35.04
- +25 ;;^UTILITY(U,$J,358.3,21576,2)
- +26 ;;=^5011790
- +27 ;;^UTILITY(U,$J,358.3,21577,0)
- +28 ;;=M35.00^^70^921^59
- +29 ;;^UTILITY(U,$J,358.3,21577,1,0)
- +30 ;;=^358.31IA^4^2
- +31 ;;^UTILITY(U,$J,358.3,21577,1,3,0)
- +32 ;;=3^Sicca Syndrome,Unspec
- +33 ;;^UTILITY(U,$J,358.3,21577,1,4,0)
- +34 ;;=4^M35.00
- +35 ;;^UTILITY(U,$J,358.3,21577,2)
- +36 ;;=^5011786
- +37 ;;^UTILITY(U,$J,358.3,21578,0)
- +38 ;;=M32.10^^70^921^62
- +39 ;;^UTILITY(U,$J,358.3,21578,1,0)
- +40 ;;=^358.31IA^4^2
- +41 ;;^UTILITY(U,$J,358.3,21578,1,3,0)
- +42 ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
- +43 ;;^UTILITY(U,$J,358.3,21578,1,4,0)
- +44 ;;=4^M32.10
- +45 ;;^UTILITY(U,$J,358.3,21578,2)
- +46 ;;=^5011753
- +47 ;;^UTILITY(U,$J,358.3,21579,0)
- +48 ;;=M32.9^^70^921^61
- +49 ;;^UTILITY(U,$J,358.3,21579,1,0)
- +50 ;;=^358.31IA^4^2
- +51 ;;^UTILITY(U,$J,358.3,21579,1,3,0)
- +52 ;;=3^Systemic Lupus Erythematosus,Unspec
- +53 ;;^UTILITY(U,$J,358.3,21579,1,4,0)
- +54 ;;=4^M32.9
- +55 ;;^UTILITY(U,$J,358.3,21579,2)
- +56 ;;=^5011761
- +57 ;;^UTILITY(U,$J,358.3,21580,0)
- +58 ;;=M34.2^^70^921^63
- +59 ;;^UTILITY(U,$J,358.3,21580,1,0)
- +60 ;;=^358.31IA^4^2
- +61 ;;^UTILITY(U,$J,358.3,21580,1,3,0)
- +62 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
- +63 ;;^UTILITY(U,$J,358.3,21580,1,4,0)
- +64 ;;=4^M34.2
- +65 ;;^UTILITY(U,$J,358.3,21580,2)
- +66 ;;=^5011780
- +67 ;;^UTILITY(U,$J,358.3,21581,0)
- +68 ;;=M34.81^^70^921^64
- +69 ;;^UTILITY(U,$J,358.3,21581,1,0)
- +70 ;;=^358.31IA^4^2
- +71 ;;^UTILITY(U,$J,358.3,21581,1,3,0)
- +72 ;;=3^Systemic Sclerosis w/ Lung Involvement
- +73 ;;^UTILITY(U,$J,358.3,21581,1,4,0)
- +74 ;;=4^M34.81
- +75 ;;^UTILITY(U,$J,358.3,21581,2)
- +76 ;;=^5011781
- +77 ;;^UTILITY(U,$J,358.3,21582,0)
- +78 ;;=M34.82^^70^921^65
- +79 ;;^UTILITY(U,$J,358.3,21582,1,0)
- +80 ;;=^358.31IA^4^2
- +81 ;;^UTILITY(U,$J,358.3,21582,1,3,0)
- +82 ;;=3^Systemic Sclerosis w/ Myopathy
- +83 ;;^UTILITY(U,$J,358.3,21582,1,4,0)
- +84 ;;=4^M34.82
- +85 ;;^UTILITY(U,$J,358.3,21582,2)
- +86 ;;=^5011782
- +87 ;;^UTILITY(U,$J,358.3,21583,0)
- +88 ;;=M34.83^^70^921^66
- +89 ;;^UTILITY(U,$J,358.3,21583,1,0)
- +90 ;;=^358.31IA^4^2
- +91 ;;^UTILITY(U,$J,358.3,21583,1,3,0)
- +92 ;;=3^Systemic Sclerosis w/ Polyneuropathy
- +93 ;;^UTILITY(U,$J,358.3,21583,1,4,0)
- +94 ;;=4^M34.83
- +95 ;;^UTILITY(U,$J,358.3,21583,2)
- +96 ;;=^5011783
- +97 ;;^UTILITY(U,$J,358.3,21584,0)
- +98 ;;=M34.9^^70^921^67
- +99 ;;^UTILITY(U,$J,358.3,21584,1,0)
- +100 ;;=^358.31IA^4^2
- +101 ;;^UTILITY(U,$J,358.3,21584,1,3,0)
- +102 ;;=3^Systemic Sclerosis,Unspec
- +103 ;;^UTILITY(U,$J,358.3,21584,1,4,0)
- +104 ;;=4^M34.9
- +105 ;;^UTILITY(U,$J,358.3,21584,2)
- +106 ;;=^5011785
- +107 ;;^UTILITY(U,$J,358.3,21585,0)
- +108 ;;=J84.170^^70^921^16
- +109 ;;^UTILITY(U,$J,358.3,21585,1,0)
- +110 ;;=^358.31IA^4^2
- +111 ;;^UTILITY(U,$J,358.3,21585,1,3,0)
- +112 ;;=3^Interstitial Lung Dis w/ Progressive Fibrotic Phenotype in Dis Classd Elsewhere
- +113 ;;^UTILITY(U,$J,358.3,21585,1,4,0)
- +114 ;;=4^J84.170
- +115 ;;^UTILITY(U,$J,358.3,21585,2)
- +116 ;;=^5159208
- +117 ;;^UTILITY(U,$J,358.3,21586,0)
- +118 ;;=J84.178^^70^921^17
- +119 ;;^UTILITY(U,$J,358.3,21586,1,0)
- +120 ;;=^358.31IA^4^2
